ERAS | Erasca, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.7800 - 2.9286
52 Week Range	1.5100 - 3.45
Beta	1.12
Implied Volatility	262.88%
IV Rank	30.30%
Day's Volume	1,001,156
Average Volume	1,943,087
Shares Outstanding	282,504,000
Market Cap	791,011,200
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-07-16

Valuation
Profitability
Growth
Health
P/E Ratio	-3.01
Forward P/E Ratio	N/A
EPS	-0.93
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	126
Country	USA
Website	ERAS

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

ERAS's peers: AADI, ARQT, BCAB, BCDA, CLSD, CNTA, CORT, CYCN, DSGN, DYN, IPSC, NGM, KROS, GLUE, GRCL, THRX, EWTX, CCCC, MLYS, CGEM, SANA, OLMA, LIFE, ZNTL, RLAY, STOK, PLRX, BDTX, ARVN, FBRX, GBIO, GRTS, IFRX, IGMS, IMAB, IMCR, IMUX, IOBT, ITOS, KRON, KURA, LGVN, LUMO, LVTX, MDXG, MGTX, MTEM, NNVC, SYBX, TYRA, URGN, VCNX, VOR, VTVT, XBIT, XNCR, YMAB, ZLAB, IVVD, PROK, OABI

*Chart delayed

Analyzing fundamentals for ERAS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see ERAS Fundamentals page.

Watching at ERAS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ERAS Technicals page.